SANTA MONICA, Calif., Nov. 28 /PRNewswire-FirstCall/ -- AidaPharmaceuticals, Inc.  today announced that the Company has successfully completed Phase II field testing of its anti-cancer drug, Rh-Apo2L. The product of over a decade of research, Rh-Apo2L is intendedto be a new drug therapy using a recombinant protein produced by geneticengineering. The drug is designed as a highly-targeted therapy with directfunction on cancer cells. Assuming successful completion of all testingphases and approval of the drug by China's State Food and Drug Administration (SFDA), Aida expects to have Rh-Apo2L on the market during the third quarterof 2008.

Phase 2 testing results thus far have shown strong efficacy in treatinglung cancer (non-small cell), non-Hodgkins lymphoma, stomach cancer, pancreatic cancer and kidney cancer. Shanghai Qiaer, Aida's research subsidiary, has reduced the key cancer targets to the three main diseaseswhich Rh-Apo2L has shown the most efficacy and which have the most market potential. These three cancer targets will be announced at a later date,pending successful trials. Formal results will also be released afterclinical tests are completed. After that, the company will apply for theapproval of commencement of Phase III clinical trials from SFDA.

About Aida Pharmaceuticals

Aida Pharmaceuticals is a product-focused pharmaceuticals company engagedin the formulation, clinical testing, registration, manufacture, sales andmarketing of advanced pharmaceutical and genetic products in mainland China.The Company's mission is to discover, develop and market meaningful newtherapies that improve human health. Aida Pharmaceuticals, in operation sinceMarch 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMPcertified in China and ISO9002 certified for quality assurance and ISO14000 certified for ecologically-friendly practices.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995

With the exception of historical information, the matters discussed inthis news release are forward-looking statements that involve a number ofrisks and uncertainties. The actual future results of Aida Pharmaceuticals could differ significantly from those statements. Factors that could causeactual results to differ materially include risks and uncertainties such asthe inability to finance the company's operations, inability to hire andretain qualified personnel, and changes in the general economic climate. Insome cases, you can identify forward-looking statements by terminology such as"may," "will," "should," "expect," "plan," "anticipate," "believe,""estimate," "predict," "potential" or "continue," the negative of such terms,or other comparable terminology. These statements are only predictions.Although we believe that the expectations reflected in the forward-lookingstatements are reasonable, such statements should not be regarded as are presentation by Aida Pharmaceuticals, or any other person, that suchforward-looking statements will be achieved. We undertake no duty to updateany of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautionednot to place undue reliance on such forward-looking statements.SOURCE Aida Pharmaceuticals, Inc. Ashley Hull, +1-310-450-9100, , for AidaPharmaceuticals, Inc.